|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.640 CAD | +3.80% |
|
+12.33% | +25.19% |
Company Valuation: Cardiol Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 142 | 43.96 | 71.77 | 151 | 130.4 | 182.1 | - | - |
| Change | - | -69.05% | 63.28% | 110.34% | -13.65% | 39.71% | - | - |
| Enterprise Value (EV) 1 | 142 | 43.96 | 36.84 | 120.4 | 108.9 | 167.1 | 171.9 | 182.1 |
| Change | - | -69.05% | -16.19% | 226.78% | -9.5% | 53.4% | 2.84% | 5.97% |
| P/E | -3.19x | -1.41x | -2.5x | -3.63x | -3.36x | -4.39x | -6.8x | 43.1x |
| PBR | - | - | 2.55x | 6.18x | 6.41x | 8.98x | 16.5x | - |
| PEG | - | 0x | 0.2x | -0.2x | 0.1x | 0.57x | 0.2x | -0x |
| Capitalization / Revenue | 1,803x | - | - | - | - | - | 54.8x | 5.01x |
| EV / Revenue | 1,803x | - | - | - | - | - | 51.8x | 5.01x |
| EV / EBITDA | -4.74x | -1.07x | -1.25x | -3x | -3.18x | -7.1x | -10.8x | -8.83x |
| EV / EBIT | -3.67x | -1.06x | -1.24x | -2.99x | -3.17x | -4.76x | -6.4x | 37.8x |
| EV / FCF | -6.03x | - | -1.46x | -4.8x | -4.56x | -8.23x | -36.7x | - |
| FCF Yield | -16.6% | - | -68.5% | -20.8% | -21.9% | -12.1% | -2.72% | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.73 | -0.49 | -0.44 | -0.51 | -0.39 | -0.36 | -0.2325 | 0.0367 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 0.0788 | - | - | - | - | - | 3.321 | 36.32 |
| EBITDA 1 | -29.95 | -41.12 | -29.54 | -40.11 | -34.21 | -23.54 | -15.88 | -20.62 |
| EBIT 1 | -38.66 | -41.34 | -29.79 | -40.28 | -34.32 | -35.09 | -26.87 | 4.821 |
| Net income 1 | -31.64 | -30.93 | -28.13 | -36.68 | -33.82 | -35.21 | -30.57 | -8.68 |
| Net Debt 1 | - | - | -34.93 | -30.58 | -21.42 | -15.01 | -10.26 | - |
| Reference price 2 | 2.330 | 0.690 | 1.100 | 1.850 | 1.310 | 1.580 | 1.580 | 1.580 |
| Nbr of stocks (in thousands) | 60,954 | 63,703 | 65,247 | 81,603 | 99,514 | 115,272 | - | - |
| Announcement Date | 23/3/22 | 28/3/23 | 1/4/24 | 31/3/25 | 31/3/26 | - | - | - |
1CAD in Million2CAD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -4.39x | - | -7.1x | - | 130M | ||
| 35.1x | 6.14x | 18.98x | 0.94% | 50.35B | ||
| -23.1x | 337.19x | -21.24x | -.--% | 39.21B | ||
| 25.17x | 2.79x | 12.05x | -.--% | 34.52B | ||
| 46.88x | 4.72x | 30.24x | -.--% | 34.6B | ||
| 27.13x | 7.96x | 19.97x | 0.42% | 27.05B | ||
| 31.25x | 5.03x | 22.91x | -.--% | 15.11B | ||
| 24.07x | 2.05x | 9x | 1.11% | 13.85B | ||
| 24.32x | 1.93x | 11.7x | -.--% | 13.18B | ||
| Average | 20.71x | 45.98x | 10.72x | 0.31% | 25.33B | |
| Weighted average by Cap. | 22.86x | 62.03x | 12.06x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CRDL Stock
- Valuation Cardiol Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
















